| Robin Woollens Lynn, CRNP | |
|
175 Martin Ave, Suite 125, Ephrata, PA 17522-1761 | |
| (717) 721-5700 | |
| (717) 721-5712 |
| Full Name | Robin Woollens Lynn |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 175 Martin Ave, Ephrata, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437512258 | NPI | - | NPPES |
| 103106140 | Medicaid | PA |
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
While an increasing number of H1N1 (swine flu) vaccines are available in the U.S., "more than half of American adults say they still don't want it, and one-third of parents say they don't want their children to get it either, according to two surveys," the Washington Post reports. "As of this week, 111 million doses of vaccine against the pandemic strain of H1N1 flu have been released to states and cities.
Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes drug formulation and use claims relating to Diffusion's entire family of first-in-class new chemical entities. Diffusion Pharmaceuticals is commercializing this family of first-in-class drug candidates to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level.
The Department of Justice reached a settlement today with the Idaho Orthopaedic Society, an orthopedic practice group and five orthopedists that will prohibit them from conspiring with competing physicians in the Boise, Idaho, area to deny medical care to injured workers and to engage in group boycotts to obtain higher fees.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robin Woollens Lynn, CRNP 3421 Concord Rd, York, PA 17402-9001 Ph: (717) 721-5712 | Robin Woollens Lynn, CRNP 175 Martin Ave, Suite 125, Ephrata, PA 17522-1761 Ph: (717) 721-5700 |
News Archive
While an increasing number of H1N1 (swine flu) vaccines are available in the U.S., "more than half of American adults say they still don't want it, and one-third of parents say they don't want their children to get it either, according to two surveys," the Washington Post reports. "As of this week, 111 million doses of vaccine against the pandemic strain of H1N1 flu have been released to states and cities.
Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products.
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes drug formulation and use claims relating to Diffusion's entire family of first-in-class new chemical entities. Diffusion Pharmaceuticals is commercializing this family of first-in-class drug candidates to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level.
The Department of Justice reached a settlement today with the Idaho Orthopaedic Society, an orthopedic practice group and five orthopedists that will prohibit them from conspiring with competing physicians in the Boise, Idaho, area to deny medical care to injured workers and to engage in group boycotts to obtain higher fees.
› Verified 3 days ago